This release includes forward-looking statements concerning the companies' future development plans for HyQ. These forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including actions of regulatory bodies and other governmental authorities , satisfaction of regulatory approval requirements, including with respect to data, competitive conditions, and other risks identified in the companies' filings with the Securities and Exchange Commission, including reports on Forms 10-K and 10-Q. Neither Baxter nor Halozyme undertake any duty to update their forward-looking statements .
Baxter Media Contacts
Deb Spak, 847-948-2349
Brian Kyhos, 847-948-4210
Baxter Investor Contacts Mary Kay Ladone, 847-948-3371 Clare Trachtman, 847-948-3085
Halozyme Therapeutics Investor/Media Contact Anne Erickson, Executive Director858-704-8264, firstname.lastname@example.org
SOURCE Halozyme Therapeutics, Inc.